257 related articles for article (PubMed ID: 32206779)
1. Increased mTOR activation in idiopathic multicentric Castleman disease.
Arenas DJ; Floess K; Kobrin D; Pai RL; Srkalovic MB; Tamakloe MA; Rasheed R; Ziglar J; Khor J; Parente SAT; Pierson SK; Martinez D; Wertheim GB; Kambayashi T; Baur J; Teachey DT; Fajgenbaum DC
Blood; 2020 May; 135(19):1673-1684. PubMed ID: 32206779
[TBL] [Abstract][Full Text] [Related]
2. Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease.
Fajgenbaum DC; Langan RA; Japp AS; Partridge HL; Pierson SK; Singh A; Arenas DJ; Ruth JR; Nabel CS; Stone K; Okumura M; Schwarer A; Jose FF; Hamerschlak N; Wertheim GB; Jordan MB; Cohen AD; Krymskaya V; Rubenstein A; Betts MR; Kambayashi T; van Rhee F; Uldrick TS
J Clin Invest; 2019 Aug; 129(10):4451-4463. PubMed ID: 31408438
[TBL] [Abstract][Full Text] [Related]
3. Increased mTORC2 pathway activation in lymph nodes of iMCD-TAFRO.
Phillips AD; Kakkis JJ; Tsao PY; Pierson SK; Fajgenbaum DC
J Cell Mol Med; 2022 Jun; 26(11):3147-3152. PubMed ID: 35488725
[TBL] [Abstract][Full Text] [Related]
4. Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease.
Pai RL; Japp AS; Gonzalez M; Rasheed RF; Okumura M; Arenas D; Pierson SK; Powers V; Layman AAK; Kao C; Hakonarson H; van Rhee F; Betts MR; Kambayashi T; Fajgenbaum DC
JCI Insight; 2020 May; 5(9):. PubMed ID: 32376796
[TBL] [Abstract][Full Text] [Related]
5. Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease.
Pierson SK; Shenoy S; Oromendia AB; Gorzewski AM; Langan Pai RA; Nabel CS; Ruth JR; Parente SAT; Arenas DJ; Guilfoyle M; Reddy M; Weinblatt M; Shadick N; Bower M; Pria AD; Masaki Y; Katz L; Mezey J; Beineke P; Lee D; Tendler C; Kambayashi T; Fosså A; van Rhee F; Fajgenbaum DC
Blood Adv; 2021 Sep; 5(17):3445-3456. PubMed ID: 34438448
[TBL] [Abstract][Full Text] [Related]
6. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
Fajgenbaum DC
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):318-325. PubMed ID: 30504327
[TBL] [Abstract][Full Text] [Related]
7. Targeting the mTOR pathway in idiopathic multicentric Castleman disease.
Stern RM; Berliner N
J Clin Invest; 2019 Oct; 129(10):4086-4088. PubMed ID: 31524635
[TBL] [Abstract][Full Text] [Related]
8. The clinicopathological comparison among nodal cases of idiopathic multicentric Castleman disease with and without TAFRO syndrome.
Kurose N; Futatsuya C; Mizutani KI; Kumagai M; Shioya A; Guo X; Aikawa A; Nakada S; Fujimoto S; Kawabata H; Masaki Y; Takai K; Aoki S; Kojima M; Nakamura S; Yamada S
Hum Pathol; 2018 Jul; 77():130-138. PubMed ID: 29684500
[TBL] [Abstract][Full Text] [Related]
9. Plasma proteomics identifies a 'chemokine storm' in idiopathic multicentric Castleman disease.
Pierson SK; Stonestrom AJ; Shilling D; Ruth J; Nabel CS; Singh A; Ren Y; Stone K; Li H; van Rhee F; Fajgenbaum DC
Am J Hematol; 2018 Jul; 93(7):902-912. PubMed ID: 29675946
[TBL] [Abstract][Full Text] [Related]
10. Exploring the role of insulin-like growth factor binding protein-1 in identifying idiopathic multicentric Castleman's disease types: Implications for the mTOR signaling pathway.
Sumiyoshi R; Koga T; Fukui S; Furukawa K; Momoki M; Ichinose K; Yano S; Kawakami A
Clin Immunol; 2023 Nov; 256():109798. PubMed ID: 37778714
[TBL] [Abstract][Full Text] [Related]
11. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
Fajgenbaum DC
Blood; 2018 Nov; 132(22):2323-2330. PubMed ID: 30487129
[TBL] [Abstract][Full Text] [Related]
12. Idiopathic multicentric Castleman disease and associated autoimmune and autoinflammatory conditions: practical guidance for diagnosis.
González García A; Fernández-Martín J; Robles Marhuenda Á
Rheumatology (Oxford); 2023 Apr; 62(4):1426-1435. PubMed ID: 35997567
[TBL] [Abstract][Full Text] [Related]
13. Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease.
Nabel CS; Sameroff S; Shilling D; Alapat D; Ruth JR; Kawano M; Sato Y; Stone K; Spetalen S; Valdivieso F; Feldman MD; Chadburn A; Fosså A; van Rhee F; Lipkin WI; Fajgenbaum DC
PLoS One; 2019; 14(6):e0218660. PubMed ID: 31242229
[TBL] [Abstract][Full Text] [Related]
14. Dichotomic response to interleukin-6 blockade in idiopathic multicentric Castleman disease: two case reports.
Ferrero S; Ragaini S
J Med Case Rep; 2021 Mar; 15(1):105. PubMed ID: 33676575
[TBL] [Abstract][Full Text] [Related]
15. Immune-mediated thrombocytopenia and IL-6-mediated thrombocytosis observed in idiopathic multicentric Castleman disease.
Rubenstein AI; Pierson SK; Shyamsundar S; Bustamante MS; Gonzalez MV; Milller ID; Brandstadter JD; Mumau MD; Fajgenbaum DC
Br J Haematol; 2024 Mar; 204(3):921-930. PubMed ID: 38168727
[TBL] [Abstract][Full Text] [Related]
16. Utility of renal biopsy in differentiating idiopathic multicentric Castleman disease from IgG4-related disease.
Kawanishi M; Kamei F; Sonoda H; Oba M; Fukunaga S; Egawa M; Koyama T; Sato Y; Tanabe K; Ito T
CEN Case Rep; 2023 May; 12(2):242-248. PubMed ID: 36414812
[TBL] [Abstract][Full Text] [Related]
17. Idiopathic multicentric Castleman disease treated with siltuximab for 15 years: a case report.
Lang E; Sande B; Brodkin S; van Rhee F
Ther Adv Hematol; 2022; 13():20406207221082552. PubMed ID: 35251585
[TBL] [Abstract][Full Text] [Related]
18. Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: A distinct subtype of iMCD-not otherwise specified with different clinical features and better survival.
Gao YH; Liu YT; Zhang MY; Li SY; Fajgenbaum DC; Zhang L; Li J
Br J Haematol; 2024 May; 204(5):1830-1837. PubMed ID: 38356434
[TBL] [Abstract][Full Text] [Related]
19. Bone marrow findings of idiopathic Multicentric Castleman disease: A histopathologic analysis and systematic literature review.
Belyaeva E; Rubenstein A; Pierson SK; Dalldorf D; Frank D; Lim MS; Fajgenbaum DC
Hematol Oncol; 2022 Apr; 40(2):191-201. PubMed ID: 35104370
[TBL] [Abstract][Full Text] [Related]
20. Schnitzler syndrome co-occurring with idiopathic multicentric Castleman disease that responds to anti-IL-1 therapy: A case report and clue to pathophysiology.
Soudet S; Fajgenbaum D; Delattre C; Forestier A; Hachulla E; Hatron PY; Launay D; Terriou L
Curr Res Transl Med; 2018 Sep; 66(3):83-86. PubMed ID: 30108026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
